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Introduction
Osteoporosis is a disease characterized by bone fragility and changes in bone microarchitecture, and the primary clinical outcome is the occurrence of low-impact 1D fractures. Osteoporosis affects more than 200 million people worldwide. 2D In the United States, more than 2 million osteoporosisrelated fractures occur annually, particularly in women (70%), and the rates of morbidity and mortality are high. In addition, the annual overhead costs of addressing the outcomes exceed USD 25 billion. 3C Osteoporosis fractures occur more frequently in the vertebrae, distal radius, and proximal femur. These fractures cause pain, physical incapacity, and deformities, impair quality of life, and reduce life expectancy. Hip fractures are the most severe and increase the mortality rate by 12-20% within 2 years of fracture. More than 50% of individuals who survive a hip fracture cannot live independently, and many of them need to live in institutionalized centers. 4D Low bone mineral density (BMD), especially in the femoral neck, is a strong predictor of fractures. The risk of fracture increases 2-3 times with each reduction of one standard deviation in the BMD. In addition to low BMD, it is important to identify the clinical risk factors for osteoporosis and fractures because these factors help evaluate the absolute risk of fracture on an individual basis and select the patients who are eligible for treatment. 5C Several epidemiological studies published in the past decade have highlighted the importance of risk factors for osteoporosis and fractures in Brazil. 6A 
Risk factors for postmenopausal osteoporosis and fractures
Osteoporosis does not present specific clinical manifestations until the occurrence of the first fracture. Therefore, a detailed medical history and physical examination should be performed in all patients to identify factors that may contribute to the bone mass loss, to evaluate predictive factors for future fractures, and to discard secondary causes of osteoporosis. Some risk factors may be reversed. 10D The most important risk factors associated with postmenopausal osteoporosis and fractures are age, being female, Caucasian or Asian ethnicity, previous individual and family history of fractures, low BMD of the femoral neck, low body mass index, and use of a prednisone dose ≥5.0 mg/day for more than 3 months, in addition to environmental factors, including smoking, abusive intake of alcohol (≥3 units per day), physical inactivity, and low dietary calcium intake. 11D Because of the high prevalence of secondary causes of osteoporosis, many of which are subclinical, a minimum laboratory evaluation, including complete blood count, calcium, phosphorus, alkaline phosphatase, thyroid function, dosing of serum 25 (OH) vitamin D, 24-h calciuria, simple lateral radiographs of the thoracic and lumbar spine, and measurement of the BMD of the lumbar spine and proximal femur are recommended for all patients before starting any treatment. Other specific tests should be conducted only in patients 10 
Routine tests
Complete blood count Calcium, phosphorus, and alkaline phosphatase Thyroid function tests Vitamin D (25OH) 24-hour calciuria Creatinine BMD Lateral RX of thoracic and lumbar spine
Specific exams
According to clinical suspicion with clinical suspicion of associated diseases, including gastrointestinal diseases (intestinal malabsorption syndrome, inflammatory disease, and celiac disease), endocrine disorders (primary hyperparathyroidism, thyrotoxicosis, Cushing's syndrome, hypogonadism, and diabetes mellitus), rheumatologic diseases, and chronic pulmonary diseases (Table 1) . 10D Bone remodeling markers are useful in assessing the effects of medications, aging, and diseases on the rates of bone resorption and formation in a period of time but should not be used for the diagnosis of osteoporosis or the choice of medication to be prescribed. The most used markers are serum CTx as a marker of bone resorption and serum P1NP as a marker of bone formation. Elevated serum CTx levels may indicate rapid loss of bone mass and have a moderate correlation as a risk factor for osteoporosis and fractures, regardless of the BMD. 12A,13B,14B The use of CTx in clinical practice is limited by the high variability among trials and the poor predictive value in the same patient. The levels of CTx may change rapidly in response to drug treatment; therefore, this marker may be useful in specific situations, such as the assessment of bone adhesion, bone adsorption, or failure to respond to drug treatment. 15A,16A Aromatase inhibitors, 17B GnRH analogs, 18B antiretroviral therapy, 19B and medroxyprogesterone, 20D in addition to anticonvulsants and anticoagulants, 11D have been listed as risk factors for osteoporosis.
The risk of falls should be considered in the evaluation of patients with osteoporosis because recurrent events constitute per se an independent risk factor for fractures, particularly in cases of neurological impairment, such as hemiparesis, Parkinson's disease, dementia, dizziness, alcoholism, and visual impairment. 21B However, the importance of the risk of falls is often neglected. In comparative terms, one standard deviation in the decrease in BMD increases the risk of hip fracture by approximately 2-to 2.5-fold, and a fall to the side increases the risk of hip fracture 3-to 5-fold. The risk of hip fracture increases approximately 30-fold in cases in which this type of fall increases the impact on the trochanter compared with the proximal femur. 22B
Recommendation
All patients diagnosed with osteoporosis should be evaluated for risk factors before the start of treatment for osteoporosis and fractures by conducting a careful medical history and physical examination, with minimal laboratory testing. In cases of clinical suspicion, specific laboratory tests should be requested to identify the causes of secondary osteoporosis.
Risk factors that are modifiable in postmenopausal women, including physical activity, smoking cessation, restriction of sedative and hypnotic medications, and other conditions that may reduce bone mass should be discussed. The correction of visual deficits and the implementation of measures to minimize the risk of falls, including the use of anti-slip stands and mats in the bathroom, care with slippery floors and loose carpets, improvement in lighting systems, and care with stairs and steps, are crucial.
Non-pharmacological treatment of postmenopausal osteoporosis
Evidence of the effectiveness of physical exercise in reducing the risk of falls and improving the quality of life of postmenopausal women with osteoporosis Clinical trials have revealed that the indication of supervised physical activity programs improves functional capacity, muscle strength, balance, coordination, flexibility, and quality of life. 23A,24A A study implemented an exercise program for the prevention of falls and randomized postmenopausal women (aged 55-75 years) with osteoporosis into two groups: the first group was used to evaluate progressive quadriceps strengthening and proprioception training associated with drug therapy, and the second group was used to assess drug therapy with bisphosphonate monotherapy for 18 weeks. 25B The results of this program indicated that women subjected to the exercise program had a lower incidence of falls compared with the group subjected to pharmacological treatment during a 6-month follow-up (ARR = 0.38, 95% confidence interval [CI] = 0.18-0.52, NNT = 2). 25B Similarly, another muscle-strengthening exercise program that aimed at improving postural control randomized postmenopausal women (72.8 ± 3.6 years) with osteoporosis into three intervention groups: (1) balance training with muscle strengthening; (2) balance training with stretching, and (3) controls (without physical activity). 26B After 8 weeks, women in groups 1 and 2 had significant increases in dorsiflexion force and knee flexion and an increase in range of motion. 26B A 12-month, randomized, controlled study examined the impacts of circuit exercise on mobility, balance, and the quality of life of postmenopausal women with established osteoporosis (previous vertebral fracture). Three months after the beginning of the intervention, there were significant improvements in mobility and in the quality of life domains analyzed using General Health In a recent meta-analysis published by the National Osteoporosis Foundation (NOF), the results indicated a 15% reduction in the overall relative risk of fractures (Summary Relative Risk Estimates (SRRE) = 0.85%, 95% CI = 0.73-0.98) and a 30% reduction in the risk of hip fracture (SRRE = 0.70, 95% CI = 0.56-0.87). 31A In a 7-year follow-up study, the Women's Health Initiative Calcium/Vitamin D Supplementation (WHI CaD) study evaluated 36,282 postmenopausal women aged 50-79 years (mean age of 62.4 years) with a predominance of Caucasian ethnicity (83%) and randomized the study sample to receive a combination of calcium and vitamin D3 (1000 mg/day + 400 IU/day) or placebo. During follow-up, hip BMD was significantly higher in the supplemented group, although there were no significant decreases in the risk of hip fractures (hazard ratio [HR] = 0.88, 95% CI = 0.72-1.09), clinical vertebral fractures (HR = 0.90, 95% CI = 0.74-1.1), and total fractures (HR = 0.96, 95% CI = 0.91-1.02). 32A With regard to adverse events, the occurrence of renal calculi was 17% higher in patients subjected to treatment (HR = 1.17, 95% CI = 1.02-1.34); however, no significant difference was observed for cardiovascular events, gastrointestinal disorders such as constipation, and neoplasms. 32A The evaluation of the effect of calcium supplementation on the reduction of bone loss is compromised in many studies because calcium supplementation involves vitamin D administration. 33C The optimal daily dose of calcium and the use of supplements are still controversial, particularly when considering adverse events. A Swedish cohort of patients with high daily calcium intake (>1500 mg/day considering dietary and supplemented calcium) showed a 40% increase in all-cause mortality (HR = 1.40, 95% CI = 1.17-1.67). 34B A meta-analysis involving a subpopulation of 16,718 WHI study patients who did not use calcium or vitamin D supplements at baseline and who were randomized to begin using them found significant increases in cases of acute myocardial infarction (AMI) and myocardial revascularization (p = 0.004). 35A The use of low calcium doses (<700 mg/day compared with 1400 mg/day) increased the cardiovascular risk. 36B A recent meta-analysis involving controlled and randomized studies found no significant differences in hospital admissions and deaths in women with postmenopausal osteoporosis who received calcium supplementation. 37A The results of the 10-year Multi-ethnic Study of Atherosclerosis (MESA) involving a multi-ethnic cohort reported a slight decrease in the number of cases of coronary atherosclerosis by tomography (calcium score) in female patients who ingested dietary calcium (average of 1081 mg/day). The risk of coronary calcification in patients who received calcium supplementation was 20% higher than in those who did not receive calcium supplementation (relative risk [RR] = 1.22, 95% CI = 1.07-1.39). 38A With respect to the correlation between calcium supplementation and cardiovascular events, randomized, controlled, and prospective studies rather than meta-analyses and subgroup analyses should be conducted to improve the level of evidence for clinicians. 39C It is important to highlight that the daily dietary intake of calcium in Brazil is below the IOM recommendation (average of 400 mg regardless of region, sex, and age). 40A Women older than 50 years with osteopenia or osteoporosis should be encouraged to ingest calcium preferentially from their diet. Some calculators can help identify calcium-rich foods and determine the daily intake of calcium (https://www.iofbo). 41 Calcium supplementation should be considered for patients who are intolerant to lactose or who for other reasons cannot obtain the daily recommendation.
Several calcium supplements are commercially available. Calcium bioavailability is highest in calcium carbonate and tribasic calcium phosphate (approximately 40%). Calcium carbonate causes gastrointestinal problems such as constipation and should be ingested with meals. The calcium bioavailability from calcium citrate is lower (21%); thus, more tablets are needed to reach the desired dose. The latter is commercially available and is an option for patients with nephrolithiasis or a history of gastric surgery (gastrectomy) or bariatric surgery. Calcium supplementation should not exceed 500-600 mg per dose regardless of the formulation because fractionation increases absorption. 42D
Recommendation
For women older than 50 years, it is recommended and safe to ingest up to 1200 mg of calcium per day, preferably in the diet by the consumption of milk and dairy products. In cases in which the dietary intake is not possible, calcium supplementation is advisable, and the risks and benefits should be assessed. Although calcium and vitamin D supplementation is essential for adequate bone mineralization, treatment of postmenopausal osteoporosis exclusively with calcium associated or not with vitamin D is not recommended.
Recommendations for the use of vitamin D in the treatment of postmenopausal osteoporosis
Vitamin D is a prohormone synthesized in the skin by exposure to ultraviolet B (UVB) rays from sunlight. The food sources of vitamin D are limited, and humans rely primarily on the production of this vitamin in the skin by UVB light. Vitamin D, either produced in the skin or ingested, undergoes chemical transformations to reach its active form (calcitriol), which has important functions in osteomineral physiology, particularly for intestinal absorption and calcium homeostasis. 43D,44D In addition to its role in the intestinal absorption of calcium, vitamin D has an important role in peripheral muscles and body balance and may affect the risk of falls. Vitamin D deficiency is common in patients with osteoporosis 45B and hip fractures. 46B The A meta-analysis of studies on postmenopausal women reported significant reductions in the risk of femoral neck fractures and non-vertebral fractures with vitamin D supplementation using daily doses higher than 800 IU. 50A However, the WHI group that received calcium and vitamin D supplementation presented a slight gain in bone mass in the femoral neck, but the reduction in the risk of fractures was not significant. 32A In contrast, other studies found increases in muscle strength and body balance and reduction of falls with vitamin D supplementation. 51A,52A
In adults with vitamin D deficiency [(25(OH)D < 20 ng/mL)], a loading dose of 7000 IU/day or 50,000 IU/week for 8 weeks is recommended, followed by a maintenance dose of 1000-2000 IU per day. 47D,48D Inadequate levels of vitamin D are considered a potential cause of failure of drug-based treatments for osteoporosis (significant loss of BMD and fractures). 53D,54A Despite the abundant evidence of the association between vitamin D deficiency and several diseases, high doses of vitamin D are not recommended because no phase III clinical trials with robust and consistent results are available. A study has shown that high doses of vitamin D equal to or greater than 500,000 IU given at once in annual regimens may increase the risk of falls and fractures, 55A and another study reported functional worsening in supplemented patients. 56B Other studies did not demonstrate that vitamin D replacement reduced overall mortality 57A or prevented cancer 58A and cardiovascular diseases, 59A even at high doses.
The available data are controversial. Therefore, more studies are necessary to establish cause and effect relationships between vitamin D deficiency and diseases and to determine whether vitamin D deficiency can predict worse clinical outcomes.
Recommendation
In women with postmenopausal osteoporosis, the determination of the plasma concentrations of 25(OH)D is recommended before the initiation of treatment. In vitamin D-deficient patients, replacement should be initiated at 50,000 IU per week for 8 weeks and then reassessed. As a maintenance dose, daily doses of 1000-2000 IU and serum levels higher than 30 ng/mL are recommended for the prevention of secondary hyperparathyroidism, improvement of bone mass, and reduction of the risk of falls. Treatments with high doses of vitamin D are not indicated.
Pharmacological treatment of postmenopausal osteoporosis

Indication of pharmacological treatment for women with postmenopausal osteoporosis
Osteoporosis is a significant public health problem worldwide and lacks effective therapies. Moreover, patients eligible for pharmacological intervention are not easily identified. 60C Screening and case detection strategies using bone densitometry have high specificity (can identify high-risk patients) but low sensitivity (fail to characterize correctly the patients who will present fractures). Therefore, strategies that take into account clinical risk factors can help determine the individual risk of fractures regardless of BMD measures and thus better determine the absolute risk of fracture due to osteoporosis. 61C The Fracture Risk Assessment Tool (FRAX) is the first specific model of prediction of fractures in Brazil. It is based on the original FRAX methodology, which was externally validated in several independent cohorts and calibrated using consistent retrospective epidemiological data on hip fracture and mortality. 62B,63A,64A,65A,66A
FRAX is a computer-based algorithm that calculates the 10-year probability of a major osteoporotic fracture (hip, spine, humerus, or wrist fracture) and hip fracture. The likelihood of fracture is calculated considering clinical risk factors (age, sex, and body mass index) and dichotomous risk factors (previous fragility fracture, parental history of hip fracture, current smoking, long-term use of oral glucocorticoids, rheumatoid arthritis, other causes of secondary osteoporosis, and alcohol consumption). The BMD of the femoral neck can be optionally included to improve the prediction of the risk of fractures. The probability of fracture is calculated considering the risk of fractures and death. The use of clinical risk factors and BMD measures improves the sensitivity of fracture prediction without compromising specificity. The use of FRAX in clinical practice requires the determination of the probability of fracture in which to intervene for treatment (intervention threshold) and the BMD test (evaluation thresholds). 67B 62 Many guidelines recommend that women with a previous fragility fracture be considered for intervention without the need for a BMD test (except for treatment follow-up), and a previous fracture may constitute sufficient risk to recommend treatment. 68B,69B For this reason, the intervention threshold in women without previous fracture can be adjusted to the age-specific probability of fracture similar to that of women with a previous fragility fracture, i.e., the intervention threshold (Fig. 1) is set at the "fracture threshold." This approach was well validated and demonstrated to be cost-effective. With regard to the assessment thresholds for BMD measures, two limits (Fig. 2) were established. A threshold probability below which neither treatment nor a BMD test should be considered (lower limit of assessment) is based on a 10-year likelihood of osteoporosis fracture similar to that of women without clinical risk factors, with a BMI of 25 kg/m 2 , and without BMD measurement. This approach is consistent with the recommendation, in most clinical guidelines, that individuals without clinical risk factors not be considered eligible for evaluation. ULE, upper limit of evaluation; LLE, lower limit of evaluation. 62 A threshold probability above which treatment may be recommended, regardless of the BMD, is set at 1.2 times the intervention threshold because, in cases in which patients have a fracture probability of at least 20% of the intervention threshold, a few individuals are reclassified when the odds are recalculated with the inclusion of BMD to the FRAX (UK National Osteoporosis Guideline Group -NOGG). 70D Moreover, an expert committee reviewed recent recommendations for the identification of patients at high risk for osteoporosis and fractures. 71D In view of these considerations, the following approach is recommended for decision making in Brazil. 62B Preliminary data from the BRAVOS study-a multicenter prospective study on fractures in the north, southeast, and south regions of Brazil-were accepted for publication. The results of this study can improve the calibration and the capacity of FRAX Brazil to predict fractures according to the study "Incidence and mortality of hip fractures in Joinville, a community of the south of Brazil", by Silva DMW, LazzaretiCastro M, Sejzenfeld VL, Zerbini C, Eis SH, Borba VCZ, accepted for publication in the Archives of Endocrinology and Metabolism).
Recommendation
-Patients with a history of previous fragility fracture should be considered for pharmacological treatment without the need for further evaluation by BMD measurement, although this evaluation may be appropriate, particularly in younger postmenopausal women and for treatment follow-up. -Patients with T-scores equal to or less than −2.5 SD in the lumbar spine, femoral neck, total femur, or 33% radius should be considered for pharmacological therapy. -In patients without previous fragility fractures, the treatment strategy should be based on a 10-year probability assessment using FRAX Brazil and NOGG recommendations.
What is the recommended interval to repeat the Bone Densitometry test?
In patients at high risk of fractures based on BMD or calculation, BMD should be repeated every 1 to 2 years by medical decision. In cases of significant loss of bone mass, patients should be re-evaluated for adherence to treatment, bone densitometry (equipment and acquisition and analysis protocols), and secondary causes, including vitamin D deficiency, presence of diseases, and medications. 53D,72C The drugs approved in Brazil for the treatment of osteoporosis in postmenopausal women are listed in Table 2 .
Evidence for recommending the use of hormone therapy in postmenopausal women to reduce the risk of fractures
Estrogens play an important anti-resorptive role in the bone metabolism of premenopausal women. Hypoestrogenism, which occurs after menopause, accelerates the loss of bone The WHI study was not performed only in women with osteoporosis with an indication of pharmacological treatment in the estroprogestative arm but evaluated 16,608 menopausal women aged 50-79 years and performed bone densitometry in a subgroup of 1024 participants. After 5 years of follow-up, on average, HRT with progesterone associated with conjugated equine estrogens (CEE) significantly increased BMD in the lumbar spine and femur by 4.5% and 3.7%, respectively, compared with placebo. 75A The isolated estrogen arm evaluated 10,739 hysterectomized menopausal women aged between 50 and 79 years, and densitometry was performed in a subgroup of 938 participants. After an average of 6 years, there were significant increases of 7.1% in the lumbar spine and 1.8% in the femur of the participants who received CEE compared with a 1.9% increase in the spine and a loss of 1.95% in the femur of the placebo group. 76A The WHI study is the largest randomized trial of placebocontrolled HRT with fracture data. The HRT conducted with estrogen alone (CEE at 0.625 mg/day) and the estroprogestative combination (association of CEE at 0.625 mg/day and AMP at 2.5 mg/day) showed an approximate reduction of 30% in hip fractures and clinical vertebral fractures. Furthermore, there was a significant decrease of 24-29% of all osteoporotic fractures with statistical significance. 75A,76A However, the beneficial effects on BMD were maintained only during HRT. After discontinuation, there was a loss of BMD after the first 12 months, and the rate of bone loss was similar to that of natural hypoestrogenism in postmenopausal women. 77A Therefore, discontinuation of HRT should be followed by another therapeutic option.
The risk of thromboembolism during HRT is approximately 2-fold higher in users of conventional doses (CEE at 0.625 mg/day associated with 2.5 mg of medroxyprogesterone acetate in a combined or cyclic scheme), particularly in the first year of treatment, and decreases as HRT is extended. 78B The prolonged use of HRT for more than 5 years associated estrogens and progestagens produces a small increase in the risk of breast cancer (eight cases per 10,000 women/year). 79B
Recommendation
HRT should be considered for the treatment of postmenopausal osteoporosis, particularly in women with climacteric symptoms, before the age of 60 years or within 10 years of the onset of menopause. The discontinuation of HRT results in loss of bone mass and an increase in the fracture rate; these patients should adopt another therapeutic strategy. The patients subjected to HRT should be carefully evaluated on an individual basis, and this treatment should be prescribed only when the benefits outweigh the risks.
Evidence for recommending the use of bisphosphonates (alendronate, risedronate, ibandronate, and zoledronic acid) in postmenopausal women to reduce the risk of vertebral and non-vertebral fractures
Nitrogen-containing bisphosphonates are the most prescribed class of drugs worldwide for the treatment of postmenopausal osteoporosis. These synthetic analogs of inorganic pyrophosphate bind to hydroxyapatite crystals at the sites of remodeling and inhibit osteoclast-mediated bone resorption. 80D Alendronate, risedronate, and ibandronate are administered orally at doses of 70 mg/week, 35 mg/week (or 150 mg/month), and 150 mg/month, respectively. Zoledronic acid is the only intravenous bisphosphonate approved for the treatment of postmenopausal osteoporosis at a dose of 5 mg per year. In 3-to 4-year placebo-controlled clinical trials, bisphosphonates significantly reduced the risk of osteoporotic fractures. The decrease in the absolute risk of fractures with bisphosphonates depends on the baseline risk and fracture site (vertebral versus nonvertebral fractures and hip fractures). 81A,82A,83A,84A,85A,86A
In the above studies, the benefits of bisphosphonates outweighed the risks. Overall, randomized clinical trials with bisphosphonates reported a 40-70% reduction in the risk of vertebral fracture and a 40-50% reduction in the risk of hip fracture, always associated with calcium and vitamin D. 87D Oral bisphosphonates should be taken during fasting, 30-60 min before breakfast, and with a full glass of water to ensure the maximum absorption; the decubitus position
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should be avoided after drug intake. A weekly presentation of risedronate can be taken during or shortly after breakfast. 88D Pivotal studies with bisphosphonates reported common adverse events, such as gastrointestinal disorders (nausea and esophagitis), flu-like symptoms, arthralgia, and mild myalgia. These events may be associated with poor adherence to treatment in many patients and affect the capacity of these drugs to reduce the risk of fractures. 89B Patients with esophageal and severe gastrointestinal diseases, such as hiatal hernia, stenosis, esophageal motility disorders (e.g., systemic sclerosis), esophageal varices, and Crohn's disease, should avoid these drugs. Patients with renal impairment with creatinine clearance lower than 35 mL/m, particularly elderly adults and individuals taking diuretics, should also avoid these drugs. Hypocalcemia should be assessed and corrected before the initiation of treatment. 90D Oral bisphosphonates (alendronate, risedronate, and ibandronate) are indicated for the reduction of vertebral and hip fractures in women with postmenopausal osteoporosis. In the study that led to the approval of ibandronate, this drug reduced only vertebral fractures. However, in a subgroup of patients with severe osteoporosis and BMD with T-scores lower than -3.0 SD in the femoral neck, the number of hip fractures decreased significantly. 91A Zoledronic acid is indicated for reducing vertebral, nonvertebral, and hip fractures in patients with postmenopausal osteoporosis. 92A
Prolonged use of bisphosphonates
The optimal duration of treatment with bisphosphonates in patients with osteoporosis is unknown. Data from extension studies of larger clinical trials suggest that alendronate therapy for more than 5 years does not significantly reduce the risk of fractures except for the risk of clinically diagnosed vertebral fractures. 93A In addition, post hoc analysis of the data from the FLEX study revealed that non-vertebral fractures were reduced in patients treated with alendronate for 10 years (compared with those treated for 5 years) only in individuals in whom the femoral neck T-score remained lower than −2.5 SD after 5 years of therapy or those with a previous vertebral fracture. 94D In the 3-year study of zoledronic acid, similar effects were observed, with a significant reduction in the risk of vertebral fractures, but no significant difference in the risk of nonvertebral and hip fractures in patients treated for 6 years compared with those treated for 3 years. 95A The outcomes following discontinuation of treatment with risedronate after 2 or 7 years of treatment have also been reported. The discontinuation of treatment for 1 year increased the serum levels of bone remodeling markers in both groups to values close to the baseline and decreased the BMD of the total hip, whereas the BMD of the lumbar spine and femoral neck remained unchanged. 96A Because of the accumulation of bisphosphonates in bone and its prolonged use, serious adverse events have been reported since 2003, including osteonecrosis of the jaw and atypical subtrochanteric fractures. Osteonecrosis of the jaw has been reported primarily in patients with advanced cancer who use high doses of bisphosphonates. In randomized studies in patients with advanced cancer, the incidence of osteonecrosis of the jaw was 1-2% per year with zoledronic acid, which is 10-fold higher than in patients with osteoporosis treated with the same drug.
Another severe adverse event is the atypical fracture of the femur. A recent review reported that patients presented a prodrome of thigh pain in 70% of cases, bilateral fracture in 28% cases, and healing delay in 26% cases. The exact etiology and correlation of these events with the use of bisphosphonates are not entirely understood. The ASBMR has published recommendations on these severe events in two task forces over the past 3 years. 97D,98D The concerns about the potential side effects of bisphosphonate use, along with available data on the long-term efficacy, have led to a recent reconsideration of the appropriate duration of treatment with these agents. In some patients, a period of temporary discontinuation of bisphosphonate has been suggested by experts 99D and was later endorsed by the American Association of Clinical Endocrinologists (AACE). 90D Advocates of the temporary discontinuation strategy argue that the efficacy of bisphosphonates has not been demonstrated after 5-year therapy for most low-risk patients and that the rates of side effects, such as atypical fracture of the femur and osteonecrosis of the jaw, increase with prolonged use. An ASBMR Task Force has developed an algorithm for recommending the long-term use of bisphosphonates (Fig. 3) . 87D Patients continuously using corticosteroids (>7.5 mg/d), those older than 75 years, and those with previous hip fracture should be considered for oral bisphosphonate therapies longer than 5 years. 70D A study published in the Brazilian Journal of Rheumatology (Revista Brasileira de Reumatologia) suggested a modified algorithm of the ASBMR. 100 This algorithm includes bone resorption markers in decision-making in cases of nonresponse to treatment, which is not unanimously accepted in the literature.
Recommendation
Randomized clinical trials have demonstrated the efficacy of bisphosphonates in reducing vertebral, non-vertebral, and hip fractures in patients with osteoporosis and have considered these drugs as the first-line therapy for postmenopausal osteoporosis. All bisphosphonates are effective in reducing the risk of vertebral fractures. However, only alendronate, risedronate, and zoledronic acid significantly decreased the risk of non-vertebral and hip fractures. Patients taking bisphosphonates should have sufficient levels of calcium and vitamin D. The reassessment of the use of bisphosphonates after 5 years has been proposed considering the risks and benefits for each patient.
Evidence for the use of denosumab in the treatment of osteoporosis in postmenopausal women
Denosumab is a human monoclonal antibody (IgG2 isotype) with high affinity and binding specificity for the activator receptor of nuclear factor kappa B (RANK-L), a cytokine 87 belonging to the tumor necrosis factor (TNF) family. Denosumab blocks the binding of RANK-L to RANK, its natural receptor, and decreases bone resorption by inhibiting the formation, activation, and survival of osteoclasts and increasing BMD. 101C The pivotal phase III clinical trial "Fracture REduction Evaluation of Denosumab in Osteoporosis every 6 Months" (FREEDOM) randomized 7808 women aged 60-90 years (72 ± 5.2 years) with T-scores between −2.5 and −4.0 SD (lumbar spine or femur) and treated with denosumab (60 mg every 6 months for 36 months) or placebo and observed a significant reduction (68%) in the risk of radiographic vertebral fractures in the intervention group. In addition, this treatment reduced the risk of all non-vertebral fractures by 20% (HR = 0.8; 95% CI = 0.67-0.95) and femur fractures by 40%. The risks of neoplasia, cardiovascular disease, delayed fracture healing, and hypocalcemia did not increase, and no cases of osteonecrosis of the jaw were observed. A few cases of cellulite were observed. 102A The long-term open-label extension study reported continuous increases in the BMD of the lumbar spine and hip (15.2% and 7.5%, respectively). A few cases of atypical femur fracture and mandible osteonecrosis were observed. 103A,104A
In patients with renal impairment, denosumab was effective and safe, with no need for dose adjustment because of the absence of glomerular clearance. However, hypocalcemia should be evaluated and corrected before treatment initiation. 105B A 12-month non-inferiority multicenter comparative phase III study on alendronate reported that 1189 postmenopausal women with T-scores lower than −2.0 SD in the lumbar spine or total hip were randomized to treatment with denosumab (60 mg every 6 months) or alendronate (70 mg per week).
There was a significantly higher increase in femur BMD in the first group (3.5%) compared with the second group (2.6%). 106A Another randomized non-inferiority clinical trial found that the transition from alendronate to denosumab significantly increased the total femur BMD after a 12-month interval and resulted in reduced cortical porosity and resorption markers in patients treated with denosumab compared with those treated with alendronate. 107A Consistent with the mechanism of action, the discontinuation of denosumab therapy may reverse the benefits (i.e., BMD and risk of fracture). In cases of discontinuation of denosumab therapy, switching to another treatment for osteoporosis should be considered. The temporary discontinuation of treatment of osteoporosis does not apply to denosumab. 108D
Recommendation
Denosumab is indicated for the treatment of postmenopausal osteoporosis. Pivotal studies have shown that this drug significantly reduced vertebral, non-vertebral, and hip fractures. Denosumab can be used in case of oral bisphosphonate failure, intolerance or contraindication, and in special situations as the first line of treatment, such as in patients with renal dysfunction. After 10 years of treatment, the available data indicated continuous gains in the BMD of the lumbar spine and the femur and reduction of fractures, with the same safety profile previously described, and in patients with renal dysfunction. Discontinuation of denosumab treatment may lead to reversal of the benefits obtained in BMD and increase the risk of fracture and, in this case, changing to another osteoporosis treatment should be considered. 
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Recommendation of raloxifene to postmenopausal women diagnosed with osteoporosis
Selective estrogen receptor modulators (SERMs) are a class of drugs that selectively act on selective estrogen receptors and exert agonistic or antagonistic effects on different target tissues. Raloxifene is a second-generation SERM with bone anti-resorptive activity. 109D The multicenter study "Multiple Outcomes of Raloxifene Evaluation" (MORE) evaluated 7705 postmenopausal women (average age of 66.5 years) with osteoporosis and without a history of breast or endometrial cancer and randomized the sample to treatment with placebo and either 60 or 120 mg of raloxifene per day. 110A After 36 months, the risk of vertebral fractures in women subjected to raloxifene monotherapy was significantly decreased by 30% and 50% at doses of 60 and 120 mg/day, respectively (RR = 0.7, 95% CI = 0.5-0.8 and RR = 0.5, 95% CI = 0.4-0.7) but did not modify the risk of non-vertebral and hip fractures compared with the placebo group (RR = 0.9; 95% CI = 0.8-1.1). 110A A significant increase was observed in BMD at the evaluated sites. With regard to adverse events, there was a higher risk of venous thromboembolism in the treated group compared with the placebo group (RR = 3.1; 95% CI = 1.5-6.2). 110A The increased risk of venous thromboembolism (1.5 to 3-fold higher) was the most severe adverse event of raloxifene therapy, and a previous history of thromboembolism was a contraindication to the use of this medication. The exacerbation of climacteric symptoms and a mild reduction of breast cancer risk were also observed in patients treated with raloxifene. 110A The decrease in the risk of breast cancer was confirmed in another large clinical trial involving women at high risk of breast cancer. Raloxifene has been approved for the prevention and treatment of osteoporosis in postmenopausal women and reduces the risk of breast cancer in postmenopausal women with osteoporosis. 111B
Recommendation
Raloxifene at a dose of 60 mg per day has been approved for the prevention and treatment of spinal osteoporosis in postmenopausal women without climacteric symptoms and significantly reduces vertebral fractures. This drug is also indicated for reducing the risk of breast cancer in postmenopausal women with osteoporosis. However, it is not recommended for nonvertebral and hip fractures.
Efficacy and safety of teriparatide in the treatment of postmenopausal osteoporosis
Teriparatide is homologous to the 34-amino-acid N-terminal sequence of the synthetic parathormone obtained via recombinant DNA technology (PTH 1-34 ). This drug has been approved for the initial treatment of postmenopausal osteoporosis in women at high risk of fracture or who have failed or not tolerated previous treatments for osteoporosis.
Teriparatide is considered an anabolic agent because it acts by increasing bone formation, in contrast to other drugs approved for the treatment of osteoporosis, with antiresorptive action. It has also been approved for glucocorticoidinduced osteoporosis. PTH 1-84 has also been approved in Europe. 112D The multicenter clinical trial that led to the approval of teriparatide evaluated the risk of osteoporosis fractures in 1637 postmenopausal women (average age of 69 years) with at least one moderate fracture or two mild non-traumatic vertebral fractures identified by spinal radiography. In this study, patients were randomized to treatment with teriparatide with subcutaneous doses of 20 or 40 g per day or placebo. 113A After 24 months (mean follow-up of 21 ± 3 months), there was a lower risk of new vertebral fractures (ARR = 0.096, 95% CI = 0.062-0.128, NNT = 10) and non-vertebral fractures (ARR = 0.037, 95% CI = 0.090-0.067, NNT = 26), but not femur fractures. The most frequent adverse events were headache, nausea, cramps, hypercalcemia, and hypercalciuria. 113A As with HRT, SERMs, and denosumab, the discontinuation of teriparatide monotherapy resulted in the loss of bone mass; thus, another treatment option for osteoporosis is recommended. 114B Teriparatide has been indicated for atypical fractures due to bisphosphonate monotherapy. 115D
Recommendation
Teriparatide is recommended for the treatment of postmenopausal osteoporosis in women at high risk of fractures, women with previous fractures, or women who experienced failure with or were intolerant to other forms of osteoporosis treatment. It is not indicated for treatment periods longer than 2 years. It may be recommended for atypical fractures caused by bisphosphonate monotherapy.
Evidence for recommending combined or sequential regimens for treatment of postmenopausal osteoporosis
Combined therapy
The results of clinical trials of the combination of drugs with different mechanisms of action, such as antiresorptive agents (HRT, bisphosphonates, denosumab, and SERMs) and anabolic agents (teriparatide and PTH1-84), differ depending on the evaluated associations, although these trials may have acceptable theoretical arguments from a scientific point of view.
The first double-blind, randomized study with this drug combination was conducted in 2003 by Black with 238 postmenopausal women (119 using PTH 1-84, 60 using alendronate, and 59 using the combined regimen) for 12 months. This study concluded that alendronate impaired the anabolic action of PTH 1-84 when the two drugs were combined. 116A Opposite results were obtained in a randomized, doubleblind, non-inferiority clinical trial with the combination of teriparatide and zoledronic acid compared with teriparatide monotherapy and zoledronic acid monotherapy in 412 postmenopausal women (average age of 65 ± 9 years) with osteoporosis. After 52 weeks, their respective BMDs increased 7.5%, 7.0%, and 1.4% in the lumbar spine and 2.3%, 1.1%, and 2.1%, in the femur. Therefore, teriparatide alone had a greater vertebral gain than zoledronic acid alone, and the combination promoted greater vertebral and femoral gains. However, the study did not have sufficient statistical power to evaluate fracture outcomes considering the sample size and treatment period. 117A Short-term adverse events, including nausea, chills, fatigue, fever, arthralgia, myalgia, and headache, were more common in patients treated with zoledronic acid (both combined and isolated regimens) within the first 3 days of infusion, whereas the events were similar between the three groups after this period. 117A Robust data from combination therapy were obtained in the Denosumab and Teriparatide Administration (DATA) clinical trial, which also analyzed the effects of the combined regimen. In this initial study, 100 postmenopausal women with osteoporosis were randomized to receive either denosumab 60 mg or teriparatide in standard doses or in combination. After 12 months, there was a significant increase in vertebral BMD in the combined drug group (9.1%) compared with the teriparatide monotherapy (6.2%) and denosumab monotherapy (5.5%) groups. Moreover, there was a greater increase in total femur BMD in the combined drug group (4.9%) compared with the teriparatide monotherapy (0.7%) and denosumab monotherapy (2.5%) groups. Therefore, combined therapy may be useful in patients at high risk of fractures, although no data are available on the effect of this drug on fracture reduction. 118B It is important to note that, to date, the evidence points only to the benefits of the combined therapy on BMD outcomes and bone remodeling biochemical markers. However, no data are available on fracture reduction, adverse events, and costs.
Sequential treatment
Several studies have demonstrated the rapid loss of BMD after discontinuation of therapy with PTH 1-84 and teriparatide. 116A,117A A study examined the BMD gain in women undergoing parathyroid hormone therapy followed by alendronate therapy. After 12 months, there was a significant increase in BMD with sequential therapy compared with monotherapy. 119B Treatment with anabolic agents should always be followed by bisphosphonates, denosumab, raloxifene, or HRT because these drugs are used for periods of less than 2 years and there is loss of bone mass, especially in the lumbar spine shortly after treatment discontinuation.
Recommendation
The lack of studies with outcomes in fracture reduction, safety data, and the cost of drug combinations for the treatment of postmenopausal osteoporosis is still unknown and therefore cannot be recommended by this guideline. Evidence suggests that the administration of bone resorption inhibitors such as bisphosphonate after the interruption of teriparatide therapy and with denosumab maintains the benefit of bone mass gain. In patients at high risk of fractures, including those with previous or multiple fractures and inadequate responses to previous treatments, drug combination should be considered.
Importance of the prevention of secondary fractures
Patients with recent osteoporotic fractures are at high risk for secondary fractures and usually do not receive guidance and treatment after the first fracture. Reference services specializing in refracture prevention are increasing worldwide and have shown good results regarding cost-effectiveness, including in Brazil, 120B,121D with the support of the IOF. 122D
Recommendation
The IOF has a training and capacity building program for services for the prevention of secondary fractures (Capture the Fracture ® (CTF) network; www.capturethefracture.org), and this program is growing worldwide. Specialized fracture treatment services should be encouraged to participate.
This study is an updated review (as of March 2017) of the guidelines for the treatment of postmenopausal osteoporosis. This study was conducted by the Brazilian Society of Rheumatology (Sociedade Brasileira de Reumatologia) with the collaboration of the Brazilian Medical Association (Associação Médica Brasileira -AMB), the Brazilian Federation of Gynecological Societies and Obstetrics (Federação Brasileira das Sociedades de Ginecologia e Obstetrícia -FEBRASGO), the Brazilian Society of Endocrinology and Metabology (Sociedade Brasileira de Endocrinologia e Metabologia -SBEM), the Brazilian Association of Bone Evaluation and Osteometabolism (Associação Brasileira de Avaliação Óssea e Osteometabolismo -ABRASSO), and the Brazilian Society of Orthopedics and Traumatology (Sociedade Brasileira de Ortopedia e Traumatologia -SBOT).
